# REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 Balance Sheet

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-30, accession number 0000872589-26-000025
- Page: https://plicit.ai/financials/regn/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/regn-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 41,730,600,000 US dollars
- **Current assets**: 18,446,000,000 US dollars
- **Non-current assets**: 23,284,600,000 US dollars
- **Liabilities**: 10,019,200,000 US dollars
- **Current liabilities**: 5,530,600,000 US dollars
- **Non-current liabilities**: 4,488,600,000 US dollars
- **Equity**: 31,711,400,000 US dollars
- **Accounts receivable, net**: 6,565,400,000 US dollars
- **Marketable securities**: 5,538,800,000 US dollars
- **Inventories**: 3,084,300,000 US dollars
- **Cash and cash equivalents**: 2,455,800,000 US dollars
- **Prepaid expenses and other current assets**: 801,700,000 US dollars
- **Marketable securities**: 9,828,300,000 US dollars
- **Property, plant, and equipment, net**: 5,458,900,000 US dollars
- **Deferred tax assets**: 4,381,400,000 US dollars
- **Other noncurrent assets**: 2,306,200,000 US dollars
- **Intangible assets, net**: 1,309,800,000 US dollars
- **Accrued expenses and other current liabilities**: 2,966,500,000 US dollars
- **Accounts payable**: 1,159,300,000 US dollars
- **Finance lease liabilities**: 720,000,000 US dollars
- **Deferred revenue**: 684,800,000 US dollars
- **Other noncurrent liabilities**: 2,281,600,000 US dollars
- **Long-term debt**: 1,986,600,000 US dollars
- **Deferred revenue**: 220,400,000 US dollars
- **Finance lease liabilities**: 0 US dollars
- **Retained earnings**: 37,621,400,000 US dollars
- **Additional paid-in capital**: 14,700,600,000 US dollars
- **Common stock - Common Stock**: 100,000 US dollars
- **Common stock - Class A Stock**: 0 US dollars
- **Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none**: 0 US dollars
- **Treasury Stock, at cost; 36.4 shares in 2026 and 33.7 shares in 2025**: negative 20,574,900,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 35,800,000 US dollars
- **Gross equity (calculated)**: 52,322,100,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.